Insulatard suspension for injection

Land: Armenien

Sprache: Englisch

Quelle: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

Wirkstoff:

insulin human (recombinant DNA)

Verfügbar ab:

Novo Nordisk A/S

ATC-Code:

A10AC01

INN (Internationale Bezeichnung):

insulin human (recombinant DNA)

Dosierung:

100IU/ml

Darreichungsform:

suspension for injection

Einheiten im Paket:

glass vial 10ml

Verschreibungstyp:

Prescription

Berechtigungsstatus:

Registered

Berechtigungsdatum:

2019-06-13

Gebrauchsinformation

COMBINATION OF THIAZOLIDINEDIONES AND INSULIN
MEDICINAL PRODUCTS
Cases of congestive heart failure have been reported
when thiazolidinediones were used in combination with
insulin, especially in patients with risk factors for
development of congestive heart failure. This should be
kept in mind if treatment with the combination of
thiazolidinediones and insulin medicinal products is
considered. If the combination is used, patients should be
observed for signs and symptoms of congestive heart
failure, weight gain and oedema. Thiazolidinediones
should be discontinued if any deterioration in cardiac
symptoms occurs.
AVOIDANCE OF ACCIDENTAL MIX-UPS/MEDICATION ERRORS
Patients must be instructed to always check the insulin
label before each injection to avoid accidental mix-ups
between Insulatard® and other insulin products.
INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER
FORMS OF INTERACTION
A number of medicinal products are known to interact
with the glucose metabolism.
THE FOLLOWING SUBSTANCES MAY REDUCE THE PATIENT’S
INSULIN REQUIREMENT:
Oral anti-diabetic products, monoamine oxidase inhibitors
(MAOI), non-selective beta-blocking agents, angiotensin
converting enzyme (ACE) inhibitors, salicylates, anabolic
steroids and sulphonamides.
THE FOLLOWING SUBSTANCES MAY INCREASE THE PATIENT’S
INSULIN REQUIREMENT:
Oral contraceptives, thiazides, glucocorticoids, thyroid
hormones, sympathomimetics, growth hormone and
danazol.
Beta-blocking agents may mask the symptoms of
hypoglycaemia and delay recovery from hypoglycaemia.
Octreotide/lanreotide may either increase or decrease the
insulin requirement.
Alcohol may intensify or reduce the hypoglycaemic effect
of insulin.
PREGNANCY AND LACTATION
There are no restrictions on treatment of diabetes with
insulin during pregnancy, as insulin does not pass the
placental barrier.
Both hypoglycaemia and hyperglycaemia, which can
occur in inadequately controlled diabetes therapy,
increase the risk of malformations and death _in utero._
Intensified blood glucose control and monit